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Health in Action
E
vidence-based medicine 
requires that clinical decisions 
be consistent not only with the 
best available research evidence, but 
with the values and preferences of 
the informed patient [1]. To achieve 
this goal, clinicians and patients can 
use tools, known as decision aids, that 
prepare patients for decision making 
[2] or help clinicians assist patients in 
participating in making decisions [3].
Our research group has recently 
completed the development and 
testing of such a decision aid, dubbed 
Statin Choice, for patients with diabetes 
who were considering using statins 
(medications that lower cholesterol) to 
reduce their cardiovascular risk. Statin 
Choice sought both to help clinicians 
share the evidence about potential 
beneﬁ  ts and downsides of statins and 
to create a two-way conversation that 
would enable patients to participate 
in making decisions to the extent they 
preferred. Patients’ participation could 
make the resulting decisions more 
likely to be consistent with their values 
and preferences. In addition, patient 
participation in decision making 
(i.e., cognitive investment in the 
decision and thus “ownership” of that 
decision) could enhance adherence 
to therapeutic interventions, among 
other potential beneﬁ  ts.
Here, we present the insights 
that resulted from the process we 
followed to develop this decision 
aid. In sharing these insights, our 
intent is not prescriptive (i.e., “this 
is how you should develop decision 
aids”), but rather to inspire others 
to seek innovative, yet goal-directed 
approaches to the development 
of decision aids that are not only 
evidence-based in content but also 
user-centered in their design and use.
The Problem
Type 2 diabetes mellitus is a common 
chronic condition associated with 
very high costs, both in resources 
and in human suffering and lives [4]. 
Cardiovascular events cause most 
of the diabetes-related deaths and 
disability, making the reduction of 
cardiovascular risk a focus of diabetes 
care [5]. Clinical trials have established 
that lowering cholesterol with statins 
can reduce the risk of cardiovascular 
events in patients with diabetes [6,7]. 
Current guidelines recommend the use 
of statins for most patients with type 
2 diabetes [8]. Despite the otherwise 
solid evidence base and the guideline 
recommendations, few patients take up 
statins and adhere to these medications 
over time [9,10].
A model for nonadherence to 
medications offers some explanations 
for this phenomenon [11,12], 
including use of multiple medications, 
discontinuity of care, and costs 
of medications. Limited patient 
knowledge [13] and participation 
in treatment decision making may 
also contribute to nonadherence. 
In particular, clinicians focused on 
“treating numbers” (e.g., lowering 
cholesterol to a guideline-directed 
low-density lipoprotein [LDL] 
cholesterol goal) may limit the 
participation of patients who feel 
unable to make expert judgments 
about LDL-cholesterol goals and statin 
dosage [14]. Thus, decision aids that 
express beneﬁ  ts and downsides in ways 
patients can understand and value, 
and the resulting enhanced patient 
participation in decision making, may 
improve adherence.
Some Key Observations
Figure 1 outlines the design process 
we used to develop the decision aid. 
To begin the project, we formed a 
multidisciplinary team of observers, 
including clinicians (nurses and 
doctors) that care for patients 
with diabetes, patient educators, 
and administrative personnel. We 
intentionally invited nonclinicians with 
little or no knowledge or expectation 
as to what “normally” happens during 
diabetes visits with a specialist. After 
a 30-minute training session about 
deliberate observation, note taking, 
illustration (sketching, photography 
of materials), and “artifact” collection, 
among other tasks, we asked them to 
make observations about how patients 
and clinicians made decisions in a 
subspecialty setting at a large referral 
academic group practice (i.e., being 
a “ﬂ  y on the wall” at real ofﬁ  ce visits). 
The observed parties gave verbal 
consent; no video or audio recording 
took place.
As the observers began to populate 
a board we had assembled for the 
purpose of collecting artifacts, notes, 
and photos, and shared stories about 
their observations with the entire 
group, it became obvious that there 
were no stories of patient participation 
in decision making or descriptions 
of visits in which clinicians presented 
the decision to start statins as a 
choice. Rather, it was apparent that 
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clinicians informed patients about 
their cholesterol levels and the need 
to achieve LDL-cholesterol goals 
(with no mention of a goal to reduce 
cardiovascular risk), and gave patients 
a statin prescription. While clinicians 
offered some instructions as to how 
to use the medication (e.g., “you 
should take it at night”), rarely was 
there a discussion about potential side 
effects, burden of treatment, cost, or 
consistency of this tactic with patient 
goals for life and health, unless patients 
speciﬁ  cally asked. Taking into account 
these observations and the theoretical 
models about nonadherence, we set 
out to design a decision aid.
A Proposed Solution—Creating 
the Conversation
We sought to develop a decision aid 
that could improve on the one-sided 
technical decision (which assumes 
that there is no alternative choice, 
that the aim is to lower cholesterol 
levels, that the physician will monitor 
liver tests and cholesterol levels and 
will adjust the dose as needed, and 
that the patient will comply) and 
that would better acknowledge that 
patients will make the ultimate decision 
on adherence, if not explicitly then 
through their actions (such as never 
ﬁ  lling the prescription or quitting 
taking the medication). To develop 
Statin Choice, we focused on three facets 
of the decision aid: its general content, 
how it conveys risk, and the design of 
its interface.
Content
We ﬁ  rst considered the “content” of the 
decision. This involved determining if 
the decision to use statins was indeed 
purely technical. In our view, technical 
decisions are choices that patients 
would have limited interest in making 
because the available options have 
features and potential outcomes that 
make little discernable difference, 
and because if patients were to 
participate their input would have a 
limited chance to make an important 
difference (e.g., the choice of suture 
material to close the bowel stump after 
appendectomy). When the decision 
to use statins is framed as a choice of 
tactics to lower LDL-cholesterol to a 
particular goal level, selecting a drug 
(e.g., statins) and a particular dose 
appear as purely technical decisions. 
This is, apparently, the view taken by 
the guideline developers, the clinicians, 
the patients, and our observers. As the 
phrase that one of our observers used 
suggests (“they had to be on statins”), 
the decision to take statins is not only 
perceived as a technical decision, but it 
is not perceived as a choice. Arguably, 
evidence of patient nonadherence to 
statins suggests that patients are making 
a decision about using statins, but they 
are not making this choice with their 
clinician in the ofﬁ  ce.
To create the conversation, we had 
to reconsider whether statin use in 
diabetes is really a technical decision 
in which patients have no chance to 
doi:10.1371/journal.pmed.0040233.g001
Figure 1. Developing the Statin Choice Decision Aid
The design process used to develop our decision aid involved user-centered observation and synthesis and an iterative development process. This 
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contribute. A recent review found that 
the research supporting use of statins 
to lower LDL-cholesterol to speciﬁ  c 
goals is of very low quality [15]. We 
thought such low-quality evidence 
did not support the decisions of 
guideline developers to make strong 
recommendations for lowering LDL-
cholesterol levels and of quality panels 
to make the LDL-cholesterol targets of 
these recommendations quality goals. 
However, we did ﬁ  nd high-quality 
evidence—from consistent and precise 
randomized trials [7,16] and from 
large postmarketing observational 
studies informing the potential beneﬁ  ts 
and downsides of statin use [17,18]—
supporting the use of statins to lower 
cardiovascular risk (at a ﬁ  xed “clinical 
trial” dose rather than dosing to seek 
a particular LDL-cholesterol goal). 
Because patients could meaningfully 
participate in a discussion about using 
statins to reduce their cardiovascular 
risk, we decided that the high-quality 
evidence supporting such use would 
inform the content of our decision aid.
Conveying Risk
To create a useful two-way conversation 
between patients and clinicians about 
the decision to use statins, we had to 
succeed at conveying risk. We had to 
decide how to represent cardiovascular 
risk both off and on statins. Focused 
on the need to offer patients the 
best chance to participate in the 
conversation, we decided against 
presentation formats that would 
potentially mislead patients in favor 
of statin use (i.e., presenting relative 
risk reductions) [19,20]. Several 
systematic reviews focused on effective 
risk communication have found that 
graphs reﬂ  ecting natural frequencies 
with a common denominator can 
convey risk accurately and in a way 
that patients prefer and understand 
[21–23]. We had shown that patients 
with diabetes, even those with low 
literacy skills, could understand risk 
presentations that used both words 
and graphics (e.g., green and happy 
and red and unhappy ordered faces) 
[24]. The ordered faces display has the 
additional advantage of enabling the 
presentation of information with both 
positive and negative framing (patients 
who experienced and patients who did 
not experience heart attacks).
Our choice of terminology 
represented a key decision. We avoided 
phrases such as “your risk of heart 
attacks in the next ten years…” since it 
is not possible to conﬁ  dently estimate a 
given individual’s risk from group data, 
and because that individual either will 
or will not have the heart attack in the 
next ten years (risk of 0% or 100%). 
We needed an accurate yet simple story 
to tell patients about risk. After several 
iterations, we came to:
“Imagine you are in a room with 
100 patients like you for the next 10 
years. At the end of that period you 
look back and you ﬁ  nd X people who 
have had a heart attack and 100 − X 
that have not. Notice that those who 
had the heart attack did so at some 
point during the 10 years, and that 
we cannot tell when someone will 
have a heart attack. Also note that 
we cannot tell whether you are one of 
those destined to have a heart attack 
(displayed using red and unhappy 
faces) or not (displayed using green 
and happy faces) in the next 10 
years...” 
To represent the absolute risk 
reduction with statins, we created a 
parallel presentation for a group of 
“100 patients like you” who took statins 
for ten years. In this version of the 
story, it was important to note that only 
a small proportion of patients destined 
to have heart attacks could avoid this 
outcome by taking medication and that 
statins cannot change the prognosis of 
the majority of patients. To clarify this 
key point, we added:
“Notice that we cannot tell whether 
you will be one of the green ones 
(patients who were not destined to 
have heart attacks but took medication 
anyway), yellow ones (patients 
destined to have a heart attack but 
who avoided one by using statins) 
or red ones (patients who suffered a 
heart attack despite taking statins).”
We created similar content to 
convey the risk of potential side 
effects of statins (see decision aid at 
http:⁄⁄mayoresearch.mayo.edu/mayo/
research/ker_unit/decision-aids.
cfm), with attention to the use of plain 
language [25].
The Interface
At least as important as the decisions 
we made about the content of the 
decision aid (enabling choice, based on 
high-quality evidence, quantitative, and 
both positive and negative framing) 
were decisions about the interface 
between the users and the decision aid.
Early in our development process 
[26], we invited key informants (patient 
education specialists, clinicians, 
diabetes educators, and patients) to 
brainstorm about the ideal interface 
for our decision aid. It became clear 
that there was a strong preference 
for interacting with the decision 
aid through an electronic interface 
(e.g., personal, portable, or desktop 
computers accessing interactive DVDs 
or the Internet). Some reasons for 
this included the ability to tailor the 
information according to the user, the 
possibility of updating the information 
easily, and the portability of the 
material, particularly if the material was 
placed and accessed on the Internet.
When asked to review a draft version 
of the decision aid we posted online, 
clinicians thought that this electronic 
version would allow the patient to use 
the decision aid without supervision, 
perhaps at home, in preparation for the 
visit. Patients, on the other hand, found 
themselves printing out the material to 
share its content with signiﬁ  cant others. 
An online decision aid seemed then 
likely not to have a meaningful impact 
on the conversation; furthermore, the 
format was not sufﬁ  ciently portable for 
patients who wanted to share it with 
other important parties to the decision. 
Also, this approach would place the 
onus of creating a conversation almost 
entirely on patients. Confronted 
with the expertise and authority of 
the clinicians, most patients may not 
feel comfortable enough to bring up 
concerns or questions that the decision 
aid may have provoked. From this 
insight, we decided that the decision 
aid needed to be present in the exam 
room during the consultation in 
order to have a chance at creating a 
conversation.
With the ideas of portability and 
presence in the exam room, we looked 
to booklets. Booklets could capture the 
information we wanted to share and 
have been used extensively to educate 
patients at Mayo Clinic. Interestingly, 
both patients and clinicians did not 
think the booklet would be efﬁ  cient 
enough to use during the visit, and 
clinicians thought patients would have 
to review the material ahead of time. At 
this point we decided to try a one-page 
version. Several such versions were tried PLoS Medicine  |  www.plosmedicine.org 1306 August 2007  |  Volume 4  |  Issue 8  |  e233
until, through a process of elimination 
and simpliﬁ  cation of the information, 
we arrived at a version that clinicians 
were willing to use during the visit 
with patients and that patients felt 
was a helpful snapshot of the issues of 
importance for the decision (see ﬁ  nal 
decision aid at http:⁄⁄mayoresearch.
mayo.edu/mayo/research/ker_unit/
decision-aids.cfm).
Our conﬁ  dence in this version 
was reinforced by the fact that a 
conversation quite different from those 
observed earlier was started when 
clinicians and patients tried using the 
one-page tool. If for no other reason, 
conversations were started to complete 
the information presented in the 
necessarily abbreviated and incomplete 
one-page version. Furthermore, use 
of a one-page tool required minimal 
clinician training in using the tool, 
offered extreme portability, and was 
not expensive to produce. Another key 
point is that the “bare bones” nature 
of the decision aid and its nondirective 
tone allowed clinicians the ﬂ  exibility 
to incorporate the decision aid within 
the workﬂ  ow of their visits, to use it 
within their own communication and 
decisional styles, and to express their 
own preferences.
A paper-based tool did not offer 
many opportunities for real-time 
tailoring. Thus, we created versions 
for patients at three different levels 
of risk. Each decision aid had the 
patient’s name, level of risk (estimated 
using speciﬁ  c patient characteristics 
[27]), list of interventions already 
in place that could reduce the risk 
of cardiovascular disease, the risk of 
cardiovascular events off and on statins, 
a quantitative description of potential 
harms and inconveniences, and a 
question seeking to determine whether 
the patient was ready to participate in a 
decision now or would prefer to delay 
the decision. The ﬁ  nal version also had 
graphical links with a more complete 
booklet; these links enabled the 
patient to complete the information 
in the one-page aid with the detailed 
descriptions in the booklet outside of 
the consultation.
The one-page tool does not include 
a graphical representation of the 
risk for downsides of therapy (the 
graphs are included in the booklet). 
A common temptation is to show 
the risk for downsides in the efﬁ  cacy 
graphs, rather than presenting graphs 
for each downside. As an unintended 
consequence, this presentation conveys 
the message that side effects and heart 
attacks (those experienced and those 
avoided by therapy) are mutually 
exclusive outcomes. That is, patients 
might assume that if the medication 
gave them elevated liver enzymes or 
muscle aches then they would neither 
get nor avoid heart attacks. The design 
of the one-page decision aid trusted 
that the resulting conversation would 
help patients contextualize the beneﬁ  ts 
in terms of the potential downsides.
The Result
We conducted a 98-patient clustered 
randomized trial of Statin Choice versus 
a standard educational pamphlet 
in patients with diabetes attending 
a subspecialty clinic [28]. A full 
description of the study and its results 
is available at http:⁄⁄kerunit.e-bm.org. 
We found that patients expressed a 
strong preference for the decision aid 
and a majority recommended it for 
other patients considering the same 
choice. The majority also requested 
a similar tool for future important 
decisions. The decision aid also 
proved effective in communicating 
information about pros and cons and 
in communicating risk and absolute 
risk reduction. This, in turn, reduced 
patient uncertainty about the best 
course of action and increased the 
proportion of patients who adhered to 
statins at three months [28].
Our analyses of the videotaped 
encounters in this trial substantiate 
the observation that, in most cases, 
the decision aid helped create a 
conversation about statins. Using the 
OPTION scale, a validated scale that 
quantiﬁ  es the extent to which clinicians 
involve patients in decision making 
[29], on the videotapes, we found 
substantial increase in the degree of 
patient involvement in decision making 
whenever the decision aid was used 
during the visit.
The resulting decision aid satisﬁ  ed 
international consensus-based 
standards for decision aids [30]. 
However, as with most complex 
interventions, it is difﬁ  cult to measure 
the relative contributions of each 
of the design features and their 
interaction. Large samples and design 
permutations in content, interface, and 
implementation would be necessary. 
Our approach has been pragmatic: 
let the evidence accumulated thus far 
about effective risk communication and 
early and frequent user input guide the 
design process. The results up to this 
point support this approach.
Furthermore, it is striking that 
our results are consistent with the 
experience of other developers who 
have learned, through different 
empirical and experiential approaches, 
the value of preserving ﬂ  exibility, 
optimizing the information content 
and interface, determining the 
appropriate technology for the 
purpose, and ensuring patient and 
clinician input throughout the process 
to enhance its acceptability [31,32].
In summary, we designed the decision 
aid Statin Choice to help clinicians create 
a conversation about medications 
with patients with diabetes. This new 
conversation is more patient-centered 
and evidence-based, and therefore more 
likely to achieve the goal we pursued: 
that the decisions made during the visit 
be more consistent with the evidence 
and the values and preferences of the 
informed patient.  
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